Financial Performance - Silexion successfully raised approximately $9.5 million in gross proceeds during Q3 2025, increasing cash and cash equivalents to $9.2 million, up from $3.5 million at the end of Q2 2025[5] - The net loss for Q3 2025 was $3.3 million, or ($2.88) per share, representing a decrease of approximately 72.3% from a net loss of $11.9 million, or ($274.25) per share, in Q3 2024[10] - Shareholders' equity rose to $7.0 million as of September 30, 2025, a substantial improvement from a capital deficiency of $4.0 million at year-end 2024[5] - The net loss for the nine months ended September 30, 2025, was $7,500,000, a reduction of 49.3% from $14,772,000 in 2024[20] - Loss per share for the nine months ended September 30, 2025, was $10.36, compared to $754.85 in the same period of 2024[20] - The operating loss for the three months ended September 30, 2025, was $3,292,000, down from $8,036,000 in the same period of 2024[20] - The net loss for the three months ended September 30, 2025, was $3,262,000, compared to $11,860,000 in 2024, reflecting a 72.5% improvement[20] - The company reported a loss before income tax of $7,497,000 for the nine months ended September 30, 2025, down from $14,763,000 in 2024[20] Expenses - Research and Development (R&D) expenses for Q3 2025 were $2.2 million, a decrease of 31.3% compared to $3.2 million in Q3 2024, primarily due to the absence of non-cash share-based compensation expenses[10] - General and Administrative (G&A) expenses for Q3 2025 were $1.1 million, down 77.1% from $4.8 million in Q3 2024, mainly due to the absence of non-cash share-based compensation expenses[10] - Total operating expenses for the nine months ended September 30, 2025, were $7,226,000, a decrease of 32.9% from $10,671,000 in the same period of 2024[20] - Research and development expenses for the nine months ended September 30, 2025, were $3,765,000, down 23.8% from $4,944,000 in 2024[20] - General and administrative expenses for the nine months ended September 30, 2025, were $3,461,000, a decrease of 39.7% compared to $5,727,000 in 2024[20] - Financial expenses for the nine months ended September 30, 2025, were $271,000, a decrease from $4,092,000 in 2024[20] Assets and Compliance - Silexion's total assets as of September 30, 2025, were $11.6 million, significantly up from $2.9 million as of December 31, 2024[17] - Silexion regained compliance with Nasdaq listing requirements, confirming continued listing on the Nasdaq Capital Market as of September 23, 2025[6] Clinical Development - The company is on track to initiate Phase 2/3 clinical trials for SIL204 in the first half of 2026, with regulatory submissions expected in Q4 2025 and Q1 2026[2] - SIL204 demonstrated high efficacy against five KRAS-driven cancer types, successfully killing cancer cells across multiple mutations, including those found in pancreatic, lung, colorectal, and gastric cancers[3] - Silexion selected AMS Advanced Medical Services GmbH as its contract research organization to support the upcoming Phase 2/3 clinical trials, leveraging their extensive oncology experience[4]
Silexion Therapeutics Corp(SLXN) - 2025 Q3 - Quarterly Results